Rossari Biotech Ltd's Q3FY25 Quarter Results
- 1d ago
Result Summary
- Rossari Biotech Ltd reported a 2.8% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 9.8%.
- Its expenses for the quarter were up by 4.4% QoQ and 12.3% YoY.
- The net profit decreased 10.3% QoQ and decreased 7.8% YoY.
- The earnings per share (EPS) of Rossari Biotech Ltd stood at 5.7 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 513.28 | 499.07 | 467.27 | 2.8% | 9.8% |
Total Expenses | 471.23 | 451.25 | 419.51 | 4.4% | 12.3% |
Profit Before Tax | 42.05 | 47.82 | 47.76 | -12.1% | -12.0% |
Tax | 10.68 | 12.78 | 13.39 | -16.4% | -20.2% |
Profit After Tax | 31.70 | 35.33 | 34.39 | -10.3% | -7.8% |
Earnings Per Share | 5.70 | 6.40 | 6.20 | -10.9% | -8.1% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Rossari Biotech Ltd is a prominent player in the specialty chemicals industry, primarily focusing on providing sustainable and innovative solutions across various sectors. The company's core products and services include home, personal care, and performance chemicals, textile specialty chemicals, and animal health and nutrition products. Rossari Biotech has been recognized for its commitment to research and development, aiming to deliver eco-friendly solutions. Recent major developments for the company include strategic acquisitions and expansions to broaden its product portfolio and market reach. For instance, the acquisition of companies in the specialty chemicals space has been a part of Rossari's strategy to enhance its capabilities and market presence.
Revenue
In the third quarter of the fiscal year 2025 (Q3FY25), Rossari Biotech Ltd reported a total income of ₹513.28 crores. This marks a quarter-over-quarter (QoQ) increase of 2.8% compared to the previous quarter (Q2FY25), where the total income stood at ₹499.07 crores. Year-over-year (YoY), the company's total income rose by 9.8% from ₹467.27 crores in the corresponding quarter of the previous fiscal year (Q3FY24). These figures indicate a steady rise in the company's revenue over the observed periods, reflecting its ability to enhance sales and possibly expand its market footprint.
Profitability
Rossari Biotech's profitability metrics for Q3FY25 reveal a profit before tax of ₹42.05 crores, which is a decrease of 12.1% QoQ from ₹47.82 crores reported in Q2FY25. On a YoY basis, the profit before tax also declined by 12.0% from ₹47.76 crores in Q3FY24. The tax expense for the quarter was ₹10.68 crores, down from ₹12.78 crores in the previous quarter and ₹13.39 crores in the same quarter last year, reflecting a decrease of 16.4% QoQ and 20.2% YoY. Consequently, the profit after tax for Q3FY25 amounted to ₹31.70 crores, showing a reduction of 10.3% QoQ from Q2FY25's ₹35.33 crores, and a 7.8% decline YoY from ₹34.39 crores in Q3FY24. Earnings per share (EPS) for the quarter were ₹5.70, down by 10.9% from ₹6.40 in Q2FY25 and by 8.1% from ₹6.20 in Q3FY24.
Operating Metrics
The financial data reveals trends in operating expenses and income for Rossari Biotech Ltd in Q3FY25. Total expenses were recorded at ₹471.23 crores, which represents an increase of 4.4% QoQ from ₹451.25 crores in Q2FY25, and a 12.3% rise YoY from ₹419.51 crores in Q3FY24. These figures indicate an upward trend in operating costs over both the quarterly and yearly periods. Despite the increase in expenses, the company's total income growth outpaced the rise in expenses on a yearly basis, which may suggest efficient revenue generation strategies or market conditions favoring the company's product offerings. However, the increase in expenses coupled with a decline in profitability metrics suggests an analysis of cost management strategies might be required to understand the dynamics better.
